Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
IBCL,mosunetuzumab,bispecific antibody,relapsed/refractory,follicular lymphoma,Phase I/II
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要